Mentor Capital
Mentor Capital, Inc. is a private equity firm based in Ramona, California, specializing in investments in medical and social use cannabis companies. Founded in 1985, the firm focuses on providing passive equity funding and liquidity to smaller businesses in the cannabis sector, particularly those preparing for public offerings. Mentor Capital typically invests in companies with sales exceeding $40 million and prefers to take significant equity positions while allowing founders to retain operational control. The firm aims to facilitate the application of cannabis for various medical conditions, including cancer-related symptoms and chronic pain management. Mentor Capital's strategy includes a unique approach to financing, where proceeds from new investments are distributed among participating cannabis companies, potentially increasing their valuations. This model allows cannabis founders to receive substantial cash while minimizing the equity stake given up in their businesses. While the firm retains some investments in cancer-related ventures, it is gradually transitioning to focus on the cannabis market, aiming to provide more financing to private companies within this growing industry.
Shiksa Pay is a flexible system where in the Institute can manage different categories of fees and can
manage all the needs of the Institute with related to fees collection. Using Shiksa Pay the students/parents will be able to pay online using their account or cards with ease of pay from anywhere. Shiksa Pay comes with a mobile app which gives the advantage of payment using mobile. Shiksa Pay gives control to the management of the Institute to access critical financial data related to fees on their fingertips which ensures proper financial planning and business forecast. Apart from being available on the desktop, it can be accessed from mobile and tables.
Award Winning Chocolate Truffles & the Purest Uncut Form of Cannabis Oil.
GW Pharmaceuticals is a biopharmaceutical company specializing in the discovery and development of cannabinoid-based therapeutics. Its flagship product, Epidiolex, is an oral medication approved for treating severe childhood epilepsy syndromes such as Dravet syndrome and Lennox-Gastaut syndrome. This marked the first approval of a cannabis-derived medicine by the U.S. Food and Drug Administration. The company also developed Sativex, a treatment for spasticity associated with multiple sclerosis, which is available in over 25 countries outside the U.S. In addition to these products, GW Pharmaceuticals is advancing a pipeline of cannabinoid candidates targeting various indications, including schizophrenia, autism spectrum disorder, and neonatal hypoxic ischemic encephalopathy. Founded in 1998 and headquartered in Cambridge, UK, the company operates primarily in Europe, the United Kingdom, and the United States, leveraging its expertise in drug discovery, regulatory affairs, and manufacturing to establish a leading position in the cannabinoid therapeutics market.
Bhang Chocolate is dedicated to crafting the finest gourmet chocolate, from high quality ingredients to ensure the greatest possible medicated edibles in the world.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.